SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

CGrowth Capital Inc (OTCMKTS:CGRA) didn’t start the year on a strong note and kept on hovering in a price range of $0.0010 to $0.0015 in the first quarter. It fetched minimal investor attention, with daily dollar volumes hardly exceeding $1000.

The performance

The things changed for worse for CGrowth after it reported its annual numbers for FY2014. The financial report showed that the company had cash of $1,227. Now, that’s a dismal performance. The current assets stood at $174,000 while current liabilities came massive at $1.7 million. The annual revenue was $486,000 and yearly net loss came at $561,000. The company is posting decent revenue compared to other OTC firms. However, it was offset by dismal cash and assets figure.

The financing

Considering the fact that the company is operating at a loss, it would be tough for CGrowth to support its operations. The most likely option for acquiring capital would be via the sale of equity, but the company has already opted for dilutive financing. A major part of the outstanding shares was in the form of debt conversion at a price of $0.0005 per share.

The momentum

Despite the dismal numbers, the share price of CGrowth spiked in the initial weeks of April, but things changed soon. However, it once again entered into green territory after it announced a letter of intent being signed with Wildfire Cannabis Company LLC. The news managed to boost the share price considerably and recorded gains of more than 11% on Friday’s trading session. The current week started well as share price jumped another 15.71%.

The recent decline seems to be a bit stretched and it was evident in yesterday’s momentum. The stock price of CGrowth declined more than 14% to close the trading session at $0.00690. The decline came at a share volume of 26.71 million compared to average share volume of 15.39 million.

SHARE
Previous articleAmerican Green Inc (OTCMKTS:ERBB) ZaZZZ Machines Makes Headlines At Kentucky Industrial Hemp Event
Next articleKey Announcements From KollagenX Corp (OTCMKTS:KGNX)
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.